Umgqatswa ngamnye wezonyango unikeza indlela ekhethekileyo yokwenza
Okwangoku, unyango olukhoyo kuphela lwe- celiac isifo sokutya-guten . Kodwa oko kungekudala kusenokutshintsha.
Inani labenzi beziyobisi njengamanje beqhuba izilingo zekliniki ukuvavanya ukhuseleko kunye nokusebenza kwenani leenqwelo zonyango. Ngamnye unendlela eyahlukileyo kunye nendlela yokusebenza (MOA). Kuthemba ukuba ngokukuvimbela inkqubo yolu daba, sinokuthi siphume ngokupheleleyo isifo se-celiac ngokupheleleyo kwisicatshulwa sezifo ezizimele .
Phakathi kwabathathu abatshabalalayo abathembekileyo kwipayipi leziyobisi:
INN-202 (i-Larazotide Acetate)
Ukuvuselela i-INN-202 ye-Pharmaceutical (i-larazotide acetate) isilwanyana esisebenzisa i -enzyme enamandla yokugaya ebonakala ngathi iyakwazi ukutshabalalisa i-gluten ngaphambi kokuba i-immune system ikwazi ukuphendula ngayo. Iziphumo zeSigaba sesi-II sovavanyo lwezonyango zathembisa kwaye zabonisa ukuba le nkunkuma yayiphephile kwaye ibekezeleke. I-MOA yezilwanyana zombini iyanciphisa ukuguguleka kwamathumbu xa iphoyisa ukuhamba kwee- antigens ezithintekayo kwiimathumbu .
Nangona i-INN-202 inokunciphisa kakhulu iimpawu zesifo se-celiac , akunakwenzeka ukuba umntu uya kukwazi ukutya iimali ezingenamkhawulo ze-gluten. Esinye isithintelo sokutya siya kusadingeka.
I-US Food Administration and Drug Administration (i-FDA) ilandele ngokukhawuleza isiza. Izilingo ze-Clinical Phase III ziyaqhubeka. Iziphumo zetyala zinokufumaneka ngexesha elithile ukuya ngasekupheleni kwe-2018
I-Nexvax2 Vaccine
I-Nexvax2 yiyona kuphela yonyango lomviwa ojongene nokugoma abantu ngabanye ngesifo kwaye bavumele ukuba babuyele ekudleni okuqhelekileyo. I-Nexvan2 sele iphumelele ngokuphumelelayo i-trial ye-Phase Ib kwaye ithetha inkqubo yokufudukela kwizilingo ezinkulu zeSigaba II.
I-Nexvax2 imodareyitha eklasini ephumayo yezonyango ezijolise ekuphatheni abantu abasele bachaphazeleka ngesifo.
Isekelwe kwimimiselo efanayo kunye neendlela zokudambisa izidalwa eziqhelekileyo ezisetyenziselwa ukunyuka kwesifo. Iimpawu zokugonya ezifanayo ziphantsi kophando lokuphatha izifo ezizimelayo ezifana ne-multiple sclerosis, uhlobo lwe-1 lweswekile, kunye ne-rheumatoid arthritis.
I-Nexvax2 ifuzisela ngokobomi abantu abanomdla othile (DQ2) ekhoyo kwipesenti ezingama-90 zabantu abanesifo. Ngaloo ndlela, isitofu singayi kusebenza xa ungenayo iDQ2,
Ngaphandle kwalokhu, uphando oluphambili lwimibuzo luyiyo yokuhlala ixesha elide elingakanani ixesha lokugonya. Isilingo sesigaba se-Ib senza into yokuphindaphinda ngokuphindaphindiweyo, ngelixa ezo ziphumo zithembise (abantu abaninzi banako ukugqiba umngeni mngcipheko kunabo abahlala kwindawo ye-placebo), kuya kuhlala kubonakala ukuba yintoni imithombo enamandla kwaye iqine.
Akukho gama ngelixa abaphandi beza kuqaliswa kuvavanyo lweSigaba II / III.
BL-7010
I-BL-7010 inikeza indlela eyahlukileyo yokuphatha isifo se-celiac. Esikhundleni sokujolisa amathumbu okanye impendulo engaphenduliyo, i-BL-7010 ibopha kwiprotheni ye gluten ngokwayo kwaye inqanda ikhono layo lokubamba.
I-BL-7010 yipolisi engabonakaliyo ekwazi ukufihla i-gluten kwi-enzymes enenjongo yokuyidiliza. Ngokufezekisa oku, i-immune system ayikwazi ukuqala ukuphendula ngokuzenzekelayo.
I-gluten kunye neziyobisi ziya kukhishwa emzimbeni kwisihlalo.
Emva kokuvavanywa okupheleleyo kweSigaba I no-II, abavelisi bathatha enye indlela baza baqalisa ukukhuthaza iB-7010 njengenkxaso yokutya kunokuba isichengisisi seyeza. NgoJanuwari 2016, inkampani yamukelwa imvume kulo Mbutho weYurophu kwaye njengangoku iqala ukuvavanywa kwilingo lokuphumelela kwekliniki phantsi kokuhlelwa kwecandelo lezobisi zeCandelo IIb.
ILizwi
Ngelixa lithembisa, akukacaci ukuba ingaba zeziphi iziyobisi ziyakwenza ukuba zithengise. Ekugqibeleni, nawuphi na umviwa uza kufuneka azalisekise izithembiso ezintathu ukuba ziza kuthathwa njengezifanelekileyo.
Baya ku funeka balawulwe kalula, bahlale behlala, banikezele iishedyuli ezinokufaneleka, bebekekezeleke, kwaye, ngokubalulekayo, mhlawumbi banokuhlawuleka.
Ngoko kusekho ininzi ekuphendulwa. Kodwa ngokuqhubela phambili kuphando kunye nokuqonda ngakumbi kwiindlela zesifo , sinokubona ngokukhawuleza imini apho singasayi kuhlala khona i-gluten-free.
> Umthombo:
> Wingjiranirun, M .; Kelly, C; kunye neLeffler, D. "Isimo samanje seZifo eziCeliac Developers drug". I-American Journal yeGastroenterology. 2016; 111 (6): 779-86.